Cargando…
CX3CL1 Overexpression Prevents the Formation of Lung Metastases in Trastuzumab-Treated MDA-MB-453-Based Humanized Tumor Mice (HTM)
SIMPLE SUMMARY: In about 15–18% of breast cancers the HER2 gene is amplified, which allows an anti-HER2 treatment. However, about 50% of HER2-positive patients experience de novo or acquired resistance to the antibody-based therapy with trastuzumab. Therefore, the identification of predictive marker...
Autores principales: | Wege, Anja Kathrin, Dreyer, Tobias F., Teoman, Attila, Ortmann, Olaf, Brockhoff, Gero, Bronger, Holger |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158361/ https://www.ncbi.nlm.nih.gov/pubmed/34070094 http://dx.doi.org/10.3390/cancers13102459 |
Ejemplares similares
-
IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM)
por: Wege, Anja K, et al.
Publicado: (2016) -
A novel rabbit derived anti-HER2 antibody with pronounced therapeutic effectiveness on HER2-positive breast cancer cells in vitro and in humanized tumor mice (HTM)
por: Wege, Anja Kathrin, et al.
Publicado: (2020) -
Effects of hirsuteine on MDA-MB-453 breast cancer cell proliferation
por: Meng, Jie, et al.
Publicado: (2022) -
Characterization of a novel PTEN mutation in MDA-MB-453 breast carcinoma cell line
por: Singh, Gobind, et al.
Publicado: (2011) -
Plasmid DNA delivery into MDA-MB-453 cells mediated by recombinant Her-NLS fusion protein
por: Jeyarajan, Sivakumar, et al.
Publicado: (2010)